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1 Abbreviations 
AMIR   Antibody-mediated immune response 
APC   Antigen-presenting cell  
BoLA   Bovine leukocyte antigen 
BNP   Bovine neonatal pancytopenia 
BNP-dam  Dam that has given birth to a BNP-calf 
BTV   Bluetongue virus 
BVDV   Bovine Viral Diarrhoea Virus 
CD   Cluster of differentiation 
CMIR   Cell-mediated immune response  
DCVC    S-(1,2-Dichlorovinyl)-L-cysteine 
DNA   Deoxyribonucleic acid 
dsRNA   Double-stranded RNA 
EHDV   Epizootic haemorrhagic disease virus  
FAIT   Foetal alloimmune thrombocytopenia 
hCG   Human chorionic gonadotropin 
IFN   Interferon 
IgG   Immunoglobulin G 
IgM   Immunoglobulin M 
IL   Interleukin 
IPA   Ingenuity Pathway Analysis 
ISCOM   Immune stimulating complex 
i.v.    Intravenous 
kDa   Kilodalton 
KEGG   Kyoto Encyclopedia of Genes and Genomes 
MDBK cells  Madin-Darby bovine kidney cells 
MHC   Major histocompatibility complex 
 
II 
 
mRNA   Messenger RNA 
NAIT   Neonatal alloimmune thrombocytopenia 
ncp   Noncytopathic 
NGS   Next-generation sequencing 
NI   Neonatal Isoerythrolysis 
Non-BNP-dam  Dam that has not given birth to a BNP-calf 
PBMC   Peripheral blood mononuclear cell 
p.c.i.   Post colostrum intake 
PCV-2    Porcine circovirus type 2 
PDNS    Porcine dermatitis and nephropathy syndrome 
PMWS   Postweaning multisystemic wasting syndrome 
Poly(I:C)  Polyriboinosinic acid-polyribocytidylic acid 
RBC   Red blood cells 
RIG-1   Retinoic-acid-inducible gene 1 
RNA   Ribonucleic acid 
RNA-Seq  RNA sequencing 
RT-PCR   Reverse transcriptase polymerase chain reaction 
SNP   Single nucleotide polymorphism 
Spp.    Subspecies 
ssRNA   Single-stranded RNA 
Th cell   T-helper cell 
TLR   Toll-like receptor 
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2 Introduction 
Bovine neonatal pancytopenia (BNP) is an alloimmune disease, which has recently emerged in 
newborn calves. This disease has been registered in several European countries as well as in New 
Zealand during the last few years (Bell et al., 2010b; Corbière et al., 2009; Ellis-Iversen and Colloff, 
2009; Friedrich et al., 2009c; Gentile et al., 2009; Ministry of Agriculture and Forestry - MAF - New 
Zealand, 2011; Pardon et al., 2010; Sánchez-Miguel et al., 2010; Smolenaars and Mars, 2009). In 
all of these countries a specific inactivated vaccine (PregSure® BVD) against the Bovine Viral 
Diarrhoea Virus (BVDV) had been applied, which is strongly associated with BNP (Lambton et al., 
2012; Sauter-Louis et al., 2012). This vaccine comprises a unique adjuvant and was shown to 
induce very high antibody titres against BVDV in vaccinated animals (Bastian et al., 2011; Raue et 
al., 2011). However, during aetiological investigations on BNP it was revealed that vaccination 
with PregSure® BVD additionally induces alloreactive antibodies in some vaccinated animals, 
which are directed against calf leucocytes (Bridger et al., 2011; Pardon et al., 2011). These 
alloantibodies are transferred to susceptible calves by ingestion of colostrum from these specific 
dams (Friedrich et al., 2011; Schröter et al., 2011). As a result of this BNP-colostrum intake, 
affected calves suffer from external and internal haemorrhages, marked thrombocytopenia and 
leucopenia and a depletion of the bone marrow (panmyelophthisis) (Friedrich et al., 2009c; 
Pardon et al., 2010). Although the number of observed clinical BNP-cases is low compared to the 
number of PregSure® BVD vaccinated dams or vaccination doses sold (Kasonta et al., 2012), case 
fatality is very high (Pardon et al., 2010). Besides these clinical cases of BNP, subclinical BNP-cases 
have been described. These cases show a transient thrombocytopenia and leucopenia, but no 
clinical signs characteristic of BNP (Pardon et al., 2010; Witt et al., 2011). The incidence of 
subclinical cases has not been investigated thoroughly up to now, and therefore it is possible that 
clinical cases of BNP only represent the tip of the iceberg. 
Only a subset of PregSure® BVD-vaccinated dams are known to produce colostrum which can 
induce BNP in related, but also in unrelated calves after ingestion of the respective colostrum 
(Friedrich et al., 2011; Schröter et al., 2011). A possible genetic predisposition of the dam involved 
in clinical BNP has been revealed in a study by Krappmann et al. (Krappmann et al., 2011). This 
study investigated a well-characterised cattle resource population with occurrence of clinical BNP-
cases and pointed out that all dams, which had clinical BNP-cases, were confined exclusively to 
one specific sire line of this population. 
Investigations on the target antigen of BNP-associated alloantibodies showed that alloantibodies 
bind to the surface of the Madin-Darby Bovine Kidney (MDBK) cell line, which had been used for 
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the production of PregSure® BVD (Bastian et al., 2011). The nature of the targeted antigen was 
revealed as MHC class I (Deutskens et al., 2011; Foucras et al., 2011). Hence, it was proposed that 
the vaccine was contaminated with MHC class I antigens from the MDBK cell line, which elicit the 
production of alloantibodies in BNP-dams. However, not only BNP-dams possess alloantibodies 
directed against MHC class I, but also some non-BNP-dams (Deutskens et al., 2011) and also a 
large proportion of animals experimentally vaccinated (Kasonta et al., 2012). 
So far, several questions regarding the aetiopathogenesis of BNP still remain unresolved. The 
study presented here addresses some of these questions. Firstly, a well-characterised cattle 
resource population was monitored for the incidence and for a possible genetic predisposition 
also involved in subclinical BNP-cases. Secondly, the immune response after vaccination with 
PregSure® BVD was characterised on trancriptome level with an RNA-Seq approach in order to 
gain an overview of the immune response to this viral inactivated vaccine and novel insights into 
potential characteristic immune reactions evoked by this vaccine. 
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3 Literature Review 
3.1 Bovine Neonatal Pancytopenia (BNP) 
3.1.1 Definition 
Since 2007, an increase in the number of neonatal calves showing clinical signs of a haemorrhagic 
diathesis has been documented in many European countries (Bell et al., 2010b; Ellis-Iversen and 
Colloff, 2009; Friedrich et al., 2009c; Gentile et al., 2009; Pardon et al., 2010; Sánchez-Miguel et 
al., 2010; Smolenaars and Mars, 2009). This syndrome, initially denoted as “bleeding calf 
syndrome”, “blood sweating” or “haemorrhagic diathesis”, was officially termed “Bovine Neonatal 
Pancytopenia” (BNP) at the Satellite Symposium of the European Buiatric Congress in Marseille, 
France, in 2009. Several criteria were defined in order to assign calves with a bleeding disorder as 
a BNP-case (Friedrich et al., 2009a): 
1) Bleeding disorder (typical haematological alterations may exist some days before clinical 
signs or even without clinical signs) 
2) Negative test results for Bovine Viral Diarrhoea Virus  (Panpestivirus PCR) 
3) Thrombocytopenia (< 200 G/L) and leucopenia (< 4.0 G/L) 
4) Calves younger than four weeks 
5) Calves show no signs of septicaemia 
6) Post mortem: Panmyelophthisis (Friedrich et al., 2009c) 
In addition to clinical and haematological findings indicative of BNP, the proof of a 
panmyelophthisis in calves up to the age of four weeks is considered to be the gold standard for 
defining a BNP-case. In case of a missing pathological examination, the combination of clinical and 
haematological (thrombocytopenia and leucopenia) findings associated with BNP is required for 
case confirmation (Reichmann, 2012; Sauter-Louis et al., 2012). 
 
3.1.2 Epidemiology 
Prior to 2007, sporadic cases of idiopathic haemorrhagic diathesis in neonatal calves had been 
perceived (Friedrich et al., 2009b). However, since 2007 an accumulation of calves with a bleeding 
disorder has been observed in Bavaria and thereafter also in other parts of Germany (Friedrich et 
al., 2009b; Friedrich et al., 2009c). Similar reports from other European countries like Belgium 
(Pardon et al., 2010), France (Corbière et al., 2009), the Netherlands (Smolenaars and Mars, 
2009), Great Britain and Scotland (Bell et al., 2010b; Ellis-Iversen and Colloff, 2009), Italy (Gentile 
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et al., 2009) and Ireland (Sánchez-Miguel et al., 2010) were recorded. In neighbouring countries 
like Switzerland, Austria and Denmark, which are free of BVD or where no BVD-vaccinations had 
been undertaken, no such cases were observed (Friedrich et al., 2011). In August 2011, a first case 
of BNP was registered in New Zealand (Ministry of Agriculture and Forestry - MAF - New Zealand, 
2011). 
Both genders are equally affected by BNP (Pardon et al., 2010), and the disease was also observed 
in a variety of different breeds such as Simmental, Holstein Friesian, Belgian Blue, Aberdeen 
Angus, Charolais, Blonde d’Aquitaine, Montbéliarde and Limousine (Bell et al., 2009; Corbière et 
al., 2009; Friedrich et al., 2009c; Pardon et al., 2010). Pardon et al. (Pardon et al., 2010) reported 
that 40% of BNP-calves were born to heifers, 30% to dams from 2nd parity, 25% to dams from 3rd 
parity and 5% to dams from 4th parity. Some dams gave birth to more than one BNP-calf, but not 
necessarily in subsequent years (Friedrich et al., 2011; Pardon et al., 2010). 
First observations pointed out that BNP may be linked to vaccinations against the Bovine Viral 
Diarrhoea Virus (BVDV) (Friedrich et al., 2009c). Two independently conducted epidemiological 
studies then revealed a strong association between the occurrence of BNP and the use of a 
specific inactivated vaccine against BVD (PregSure® BVD, Pfizer Animal Health) (Lambton et al., 
2012; Sauter-Louis et al., 2012). PregSure® BVD had been launched in 2004 in Germany (Kasonta 
et al., 2012) and was retracted from the European market in 2010 (Paul-Ehrlich-Institut - PEI, 
2010). Following a first case report, the vaccine was also recalled in New Zealand in 2011 (Ministry 
of Agriculture and Forestry - MAF - New Zealand, 2011). Until 28th February 2011, more than 
3.000 case reports had been registered in Germany (Paul-Ehrlich-Institut - PEI, 2011). By the end 
of August 2012, 6913 suspected BNP-cases had been reported across Europe, with a decreasing 
tendency of reported cases in 2011 and 2012 compared to previous years (Jones et al., 2013).  
BNP is a non-notifiable disease. Therefore, the precise number of cases in Germany is likely to 
have been much higher since not all cases have been reported, as a German study revealed 
(Reichmann, 2012). Considering the large amount of vaccination doses sold (Doll et al., 2013), the 
overall reported incidence of clinical cases of BNP is low (Kasonta et al., 2012; Pardon et al., 
2010). On individual farm level, the incidence rate was generally not more than 10% (Foucras et 
al., 2011; Witt et al., 2011), but there were farms with an incidence rate up to 20% (Reichmann, 
2012). There are reports of an increase of clinical BNP-cases during summer and autumn, 
potentially due to insect bites (Friedrich et al., 2009c; Pardon et al., 2010). Furthermore, field 
observations revealed a high proportion of BNP-affected herds, in which a subclinical case of BNP 
could be detected (Pardon et al., 2010). A study on a farm with a high incidence rate of BNP 
demonstrated a remarkable proportion of neonatal calves showing alterations in haematological 
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parameters without clinical signs of BNP (Witt et al., 2011). Although these studies point to the 
occurrence of subclinical cases, extensive investigations on the true incidence of subclinical BNP-
cases are missing. 
Alloreactive antibodies contained in colostrum of certain dams were shown to be the causal 
agents for inducing BNP in calves (Bridger et al., 2011; Friedrich et al., 2011; Pardon et al., 2011; 
Schröter et al., 2011). Kasonta et al. (Kasonta et al., 2012) reported that in most cases, repetitive 
vaccinations with PregSure® BVD, such as a basic immunisation consisting of two doses and a 
booster vaccination, were required for the induction of alloreactive antibodies. Varying incidences 
of BNP were observed amongst European countries and also within other European countries 
(Lambton et al., 2012). For different regions of Germany, different vaccination regimens were 
found to be a potential causative factor for varying incidences of BNP (Kasonta et al., 2012). In the 
German federal state of Bavaria, where a much higher incidence rate of BNP was observed in 
comparison to the federal state of Lower Saxony, PregSure® BVD had been applied according to 
the manufacturer’s instructions. Therefore, dams in Bavaria had received at least two doses of 
PregSure® BVD. In Lower Saxony, however, a two-step vaccination scheme, which consists of a 
primary vaccination with an inactivated BVD-vaccine like PregSure® BVD and a booster 
immunisation with a live attenuated BVD vaccine, had been applied. Thus, in Lower Saxony most 
dams had received a maximum of one dose of PregSure® BVD (Kasonta et al., 2012). In some 
cases, one dose of PregSure® BVD was still sufficient for the development of BNP-associated 
alloantibodies, as demonstrated by the very low incidence rate of BNP-cases in Lower Saxony.  
 
3.1.3 Clinical Signs 
The background for the most prominent clinical signs found in BNP-calves is a haemorrhagic 
diathesis due to thrombocytopenia. Increased bleeding tendencies can be due to defects in 
primary haemostasis like thrombocytopenia or qualitative disorders like thrombopathy. 
Underlying mechanisms for disorders in secondary haemostasis involve defects during fibrin 
formation from coagulation factors, for example caused by vitamin K antagonists or inherited 
coagulopathies (Grubbs and Olchowy, 1997). A thrombocytopenia can result from a decreased 
platelet production, increased platelet destruction, consumption of thrombocytes, or 
sequestration. 
Initially, BNP-calves are born healthy and with a normal birth weight (Bell et al., 2010b; Kappe et 
al., 2010). First abnormalities in affected calves are not necessarily signs of a bleeding disorder, 
and calves can present typical neonatal diseases such as diarrhoea, umbilical infections and/or 
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lung infections. Some calves displayed fever of unknown origin and a dull demeanour (Friedrich et 
al., 2009c). First indications of a bleeding disorder are sometimes prolonged bleeding after ear-
tagging, injections or dehorning (Bell et al., 2010b; Friedrich et al., 2009c; Klemt, 2010; Pardon et 
al., 2010). The typical clinical signs of BNP are sometimes already observed at the age of one week 
(Bell et al., 2010b; Buck et al., 2011), but mostly show up during the 2nd and 3rd week after birth 
(Friedrich et al., 2009c; Kappe et al., 2010; Klemt, 2010; Pardon et al., 2010), and up to the age of 
approximately four weeks post partum (Kappe et al., 2010; Pardon et al., 2010; Smolenaars and 
Mars, 2009). On average, the bleeding disorder becomes noticeable at the age of 12.7 days 
(Friedrich et al., 2009c) or 14 days (Smolenaars and Mars, 2009). According to Pardon et al. 
(Pardon et al., 2010), calves on average die at the age of 13 days post partum. In experimental 
studies with challenge calves, first clinical signs of a bleeding disorder were already noticed at the 
age of 3 – 4 days (small amounts of blood in faeces) (Friedrich et al., 2011). After the onset of 
obvious clinical symptoms, most affected calves die peracutely or acutely within a few days (Bell 
et al., 2010b; Friedrich et al., 2009c; Kappe et al., 2010; Klemt, 2010). Irrespective of any medical 
treatment, lethality in affected calves is high, with reports of a lethality rate ranging between 60% 
(Buck et al., 2011) up to 90% (Pardon et al., 2010). 
One of the most frequent clinical findings in BNP-affected calves is differing amounts of blood in 
the faeces, which ranges from single bloody smears to single coagula up to a bloody diarrhoea 
(Friedrich et al., 2009c). In addition, petechiae on mucous membranes are a common observation 
and can be observed mainly on the oral mucous membranes, especially sublingually, but also on 
buccal, nasal and vaginal mucosae and on the edges of the eyelids (Friedrich et al., 2009c; Pardon 
et al., 2010). In the initial phase of the disease, mucous membranes are pink (Pardon et al., 2010), 
and in the progress of the disease turn anaemic (Klemt, 2010; Pardon et al., 2010). Less common 
clinical findings are epistaxis, subscleral bleedings, haematomas and blue discolouration at the 
chin, the opening of the mouth and muzzle (Friedrich et al., 2009c; Pardon et al., 2010). Only 60% 
of clinically affected calves displayed bleedings of the skin, which resulted in the initial colloquial 
term “blood sweating” used for the disease. However, this term is misleading, because the 
bleedings do not originate from large areas, but rather from very small, punctual localisations 
(Friedrich et al., 2009c). According to Pardon et al. (Pardon et al., 2010), areas around the eyes, 
ears, the back and distal part of the limbs are mainly affected by transcutaneous bleedings, which 
might be due to insect bites (Friedrich et al., 2009c; Pardon et al., 2010). These fly bites might also 
have been the reason for a higher number of reported clinical BNP-cases during the summer and 
autumn (Friedrich et al., 2009c; Pardon et al., 2010). In first case reports, pyrexia, resistant to 
medical treatment, was revealed as a common finding in BNP-calves (Bell et al., 2010b; Friedrich 
et al., 2009c; Klemt, 2010). However, not all animals display fever, and especially in the final stage 
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of the disease calves may show hypothermia (Pardon et al., 2010). In experimental studies with 
challenge calves, only a small number of calves showed fever (Friedrich et al., 2011), and 
challenge calves did not display this symptom more frequently compared to control calves (Bell et 
al., 2013). The general condition of calves deteriorates during the course of the disease up to a 
severely depressed state and permanent recumbency (Friedrich et al., 2009c; Pardon et al., 2010). 
Along with these characteristic findings of BNP, several BNP-calves were affected by other 
infections, such as diarrhoea, umbilical infections, pneumonia or septicaemia, which did not 
respond to medical treatment (Friedrich et al., 2009c). Calves that survived clinical BNP showed 
stunted growth (Witt et al., 2011). 
 
3.1.4 Haematological Findings 
Reference ranges for blood parameters in neonatal calves differ from those applied to adults 
(Knowles et al., 2000). There are few studies only that deal with haematological profiles in 
neonatal calves (Egli and Blum, 1998; Knowles et al., 2000; Mohri et al., 2007; Tennant et al., 
1974). Studies in the context of BNP applied reference ranges of 200 – 800 G/l for thrombocytes 
(Buck et al., 2011; Friedrich et al., 2011) or 300 G/l (Kappe et al., 2010; Klemt, 2010; Witt et al., 
2011) or only 100 G/l (Pardon et al., 2010) for the threshold. For the leucocytes, reference ranges 
from 4.0 – 10.0 G/l (Friedrich et al., 2011; Pardon et al., 2010) or up to 12.0 G/l for the upper 
margin (Kappe et al., 2010; Klemt, 2010; Witt et al., 2011) were previously used. 
The most distinctive haematological aberration found in clinically affected BNP-calves is a severe 
thrombocytopenia (Bell et al., 2010b; Buck et al., 2011; Friedrich et al., 2009c; Kappe et al., 2010; 
Pardon et al., 2010) along with a normal morphology of the platelets (Buck et al., 2011; Friedrich 
et al., 2009c). Shortly before death, calves can have thrombocyte counts < 10.0 G/l (Buck et al., 
2011; Krappmann et al., 2011; Pardon et al., 2010), which is incompatible with life. Depending on 
the outcome of the disease in clinical BNP-cases, thrombocyte counts increased continually back 
to reference ranges in calves that survived BNP, whereas lethal BNP-cases showed no recovery 
from thrombocytopenia (Buck et al., 2011; Friedrich et al., 2009c; Pardon et al., 2010). In 
challenge studies, which applied a frequent haematological monitoring, platelet numbers already 
decreased during the first three hours post colostrum intake in challenge calves (Friedrich et al., 
2011). This phenomenon of decreasing thrombocyte counts after birth could also be found in 
control or healthy calves (Egli and Blum, 1998; Knowles et al., 2000; Schröter et al., 2011), 
however already being significantly less distinctive 8 hours after colostrum intake than in 
challenge calves (Bell et al., 2013). Thereafter, in healthy or control calves and BNP-affected 
calves, platelet counts again increased up to day 3 (Bell et al., 2013; Schröter et al., 2011). 
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However, after this increase, BNP-calves showed a second decline in thrombocytes, with values 
below the applied reference ranges (Bell et al., 2013; Friedrich et al., 2011; Schröter et al., 2011). 
Some animals with clinical BNP display a severe leucopenia besides a marked thrombocytopenia, 
especially shortly before death (Bridger et al., 2011; Buck et al., 2011; Friedrich et al., 2009c; 
Kappe et al., 2010; Krappmann et al., 2011; Pardon et al., 2010). However, the leucopenia does 
not always occur simultaneously with the thrombocytopenia (Schröter et al., 2011) and can show 
varying courses over time, with leucocyte counts being temporarily back above the threshold of 
4.0 G/l (Bridger et al., 2011; Friedrich et al., 2011; Schröter et al., 2011). Immunosuppression as a 
result of sustained leucopenia is likely to be the reason for attendant bacterial infections and 
lacking success of medical treatment (Friedrich et al., 2011). Leucocyte differential counts 
revealed a monocytopenia, lymphopenia (relative lymphocytosis) and neutropenia (Bell et al., 
2010b; Kappe et al., 2010; Pardon et al., 2010). After an initial significant decrease of neutrophils 
after colostrum ingestion in challenge calves, there was no significant difference in neutrophil 
counts after 8 hours post colostrum intake and thereafter in challenge calves compared to control 
animals until both groups of calves were euthanised for experimental reasons on day 10 after 
birth (Bell et al., 2013). At the time points 8 hours and 12 hours after colostral intake, challenge 
calves showed a significantly higher proportion of band neutrophils than control calves, which 
suggests myeloid stress (Bell et al., 2013). 
Anaemia was found in several calves (Bell et al., 2010b; Kappe et al., 2010; Krappmann et al., 
2011; Pardon et al., 2010), especially in the final stage of the disease (Schröter et al., 2011). The 
anaemia was normocytic and normochromic (Bell et al., 2010b). Initially it was of haemorrhagic 
nature, but then turned into an aplastic anaemia, since hardly any reticulocytes could be found in 
affected calves (Bell et al., 2010b; Friedrich et al., 2009c). In accordance with these findings, the 
packed cell volume was within applied reference ranges or below the threshold (Buck et al., 2011; 
Friedrich et al., 2011; Kappe et al., 2010; Pardon et al., 2010). 
All observed changes in peripheral blood cell counts correspond to the life span of these cells in 
the blood combined with a destruction of the bone marrow stem cells: the shortest life span can 
be found in granulocytes (less than one week), followed by thrombocytes (5 – 10 days) and 
erythrocytes (110 – 150 days) (Baker et al., 1998; Bell et al., 2013; Friedrich et al., 2009c; Mizuno 
et al., 1959). As indicated in Bell et al. (Bell et al., 2013), lymphocytes in the periphery have a 
variable lifespan. 
There are several reports either in the field or in challenge studies on calves that showed cell 
counts below the applied reference ranges in at least two haematopoietic cell lineages, but no 
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clinical symptoms consistent with BNP (Friedrich et al., 2011; Pardon et al., 2010; Schröter et al., 
2011; Witt et al., 2011). These calves were classified as subclinical BNP-calves. 
Except for a hypoproteinaemia, which might be due to the haemorrhagic diathesis, blood 
biochemical parameters did not show any abnormalities in clinically affected BNP-calves (Pardon 
et al., 2010). Bell et al. (Bell et al., 2010b) found no abnormalities in the prothrombin and 
activated partial thromboplastin times, while Pardon et al. (Pardon et al., 2010) reported of a 
slightly prolonged prothrombin time and in some calves a slightly prolonged activated partial 
thromboplastin time. In contrast, Krappmann et al. (Krappmann et al., 2011) revealed an 
extremely prolonged prothrombin time in a number of BNP-cases. Fibrinogen was either elevated 
or normal (Pardon et al., 2010). 
 
3.1.5 Pathology and Histology 
Gross pathological findings in BNP-calves revealed generalised haemorrhages in varying degrees, 
ranging from petechiae to ecchymoses or suggilations, which could be found in various organs, 
tissues and localisations (Buck et al., 2011; Friedrich et al., 2009c; Kappe et al., 2010; Klemt, 2010; 
Krappmann et al., 2011; Pardon et al., 2010). Haemorrhages were found most frequently on the 
skin and subcutaneously, especially at bony prominences, external mucosae, on the serosae, 
subepi- and subendocardially, in the meninges and in the skeletal muscle (Friedrich et al., 2009c; 
Kappe et al., 2010; Krappmann et al., 2011; Schröter et al., 2011). The gastrointestinal tract can be 
filled with coagulated blood (Krappmann et al., 2011; Pardon et al., 2010). Less common findings 
are haemorrhagic fluid in the pleura, the abdomen or intra-articular (Pardon et al., 2010). After 
venipuncture or injections, severe haemorrhages were found at respective locations (Schröter et 
al., 2011). Due to the haemorrhagic diathesis, carcasses appear anaemic (Friedrich et al., 2009c; 
Kappe et al., 2010; Klemt, 2010; Pardon et al., 2010). The bone marrow of sternum and long 
bones has a pale red appearance (Kappe et al., 2010). In challenge experiments, lymph nodes like 
prescapular or inguinal lymph nodes were found to be enlarged in some calves (Bell et al., 2013; 
Schröter et al., 2011), as well as the thymus (Bell et al., 2013). In necropsy of challenge calves, Bell 
et al. (Bell et al., 2013) showed at 10 days after first colostrum intake a significantly reduced 
length of the femurs in comparison to control calves, while Kappe et al. (Kappe et al., 2010) 
reported in BNP-calves a good nutritional condition and bodyweight according to the respective 
age at necropsy. Besides these findings, other pathological observations in several BNP-calves 
were bronchopneumonia, inflammations in the oral cavity or catharral enteritis and detection of 
pathogens associated to these diseases (Friedrich et al., 2009c; Kappe et al., 2010; Klemt, 2010; 
Krappmann et al., 2011; Pardon et al., 2010). 
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The most distinctive finding in histopathology is a depletion of the bone marrow haematopoetic 
cells (panmyelophthisis) (Bell et al., 2010b; Buck et al., 2011; Friedrich et al., 2009c; Friedrich et 
al., 2011; Kappe et al., 2010; Klemt, 2010; Krappmann et al., 2011; Pardon et al., 2010; Schröter et 
al., 2011). Depending on the degree of hypoplasia, ranging from hypo- to aplastic bone marrow, 
various numbers of precursor cells are still present, but all precursor cells of the erythroid, 
myeloid and lymphoid lineage, including megakaryocytes, are reduced (trilineage hypoplasia) (Bell 
et al., 2010b; Friedrich et al., 2009c; Kappe et al., 2010; Pardon et al., 2010; Schröter et al., 2011). 
Clusters of macrophages were found, many of them being activated and in some calves showing 
haemophagocytosis (Pardon et al., 2010). In some animals, the eosinophilic component was 
increased (Pardon et al., 2010). A comprehensive study, in which bone marrow biopsies were 
taken at 24 hours, 6 days and at necropsy 10 days after giving a standardised dose of the same 
colostrum to all challenge calves, a reduced cellularity, involving all cell lineages, was revealed 6 
days post challenge. At 10 days post colostrum ingestion, the reduced cellularity was marked, but 
small numbers of eosinophil, mature neutrophils and erythroid progenitors could still be 
detected. Hence, the destruction of the bone marrow does not affect the more mature stages of 
neutrophil, eosinophil and erythrocyte precursors (Bell et al., 2013). Areas affected by 
hypocellularity are replaced by fatty stromal tissue or filled with erythrocytes or a proteinaceous 
fluid (Bell et al., 2010b; Bell, 2011). Regarding the vascular architecture, neither damages relating 
to a vasculopathy, nor endothelial changes or transmural inflammation were detected (Pardon et 
al., 2010). An extravasation of red blood cells could be demonstrated, whereby the affected tissue 
and organ architecture did not show any abnormalities (Pardon et al., 2010). Other 
histopathological findings include a diffuse lymphoid depletion equally involving T- and B-
compartments in spleen and lymph nodes; in some calves the lymphoid depletion was also found 
in the thymus (Kappe et al., 2010; Pardon et al., 2010). There is an increase of apoptotic 
lymphocytes in lymphoid follicles (Kappe et al., 2010). Bell et al. (Bell et al., 2013) revealed wider 
cortices and no well-defined secondary follicle formation compared to control calves 10 days after 
colostral intake in lymph nodes of challenge calves. Lymphocyte depletion can be observed in the 
periarteriolar lymphoid sheets and lymphoid follicles in the spleen. Additionally the red pulp can 
display a hypocellularity (Pardon et al., 2010). 
 
3.1.6 Therapy and Prophylaxis 
Blood transfusions were undertaken in some BNP-calves. These proved to be a short term success 
only, and the lethality rate was not decreased (Buck et al., 2011; Pardon et al., 2010). On a long-
term perspective, haematological alterations like thrombocytopenia and leucopenia were not 
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improved with this approach (Pardon et al., 2010). Moreover, several attempts were made in 
treating bacterial infections and fever with different antibiotics and antiphlogistics, either without 
(Friedrich et al., 2009c; Kappe et al., 2010; Pardon et al., 2010) or with limited success (Klemt, 
2010). It had been reported that prophylactic treatment of calves with dexamethasone on day 7 
after birth resulted in a lower incidence of clinically affected BNP-calves, and haematological 
parameters also showed less dramatic deviations from reference ranges (Klemt, 2010). 
In first experimental studies with challenge calves, colostrum from specific dams was shown to be 
the key causal agent for the induction of BNP (Friedrich et al., 2011; Schröter et al., 2011). Feeding 
a group of calves with a colostrum substitute in a herd with previous BNP-incidence proved to 
prevent BNP-cases, while some calves of the same herd, which were fed colostrum from their 
own dams, showed haematological alterations or developed clinical signs of BNP (Schröter et al., 
2012). Similarly, Bell et al. (Bell et al., 2010a) reported that calves from BNP-dams were muzzled 
immediately after birth and received a colostrum substitute, which prevented development of 
BNP in these calves. Thus, feeding of mixed colostrum in herds with previous BNP-cases as well as 
colostrum from dams that are known to have had BNP-calves should be avoided. 
  
3.2 Alloimmune Diseases 
Alloimmunity is defined as an immune response towards antigens of a genetically different 
member of the same species. The prefix “allo-” means “other”. The term is most often used in 
connection with graft rejection or blood transfusions. In autoimmune diseases, with the prefix 
“auto” meaning “self”, an individual’s own tissue is attacked by the immune system. Finally, the 
prefix “xeno”, originating from “xenos”, the Greek word for “foreign”, describes a graft between 
two animals of different species (Tizard, 2012a; Tizard, 2012b). 
Cell surface molecules of red blood cells (RBC), comprising membrane proteins, glycoproteins or 
glycolipids, differ between individuals and can act as antigens (Urbaniak, 2002). In humans, more 
than 20 blood group systems have been recognised, and well-known antigens are the 
polysaccharide antigens AB0 or protein antigens such as Rhesus. Alloimmunisation against RBC 
antigens can occur during blood transfusions, pregnancy or tissue/organ transplantation, if there 
are genetic differences between donor and recipient (Urbaniak, 2002). Alloantibodies against RBC 
antigens can also preexist naturally in an individual without any previous exposure to foreign RBCs 
and are typically of IgM type (Urbaniak, 2002). After exposure to RBCs of a genetically different 
individual, the recipient will produce alloantibodies (Tizard, 2012c). RBCs of the donor will be 
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eliminated through intravascular haemolysis and phagocytosis within the recipient. Subsequent 
exposure to the same antigen will result in immediate destruction of the RBCs (Tizard, 2012c). 
Several authors pointed out that there are parallels between BNP and a condition in humans, 
namely the foetal/neonatal alloimmune thrombocytopenia (FAIT/NAIT) (Bridger et al., 2011; 
Deutskens et al., 2011; Foucras et al., 2011; Witt et al., 2011), which is considered to be the 
platelet counterpart of Rhesus Haemolytic Disease of the Newborn (RHD) (Kaplan, 2006). NAIT is 
caused by maternal alloantibodies, which are directed mainly against platelet-specific alloantigens 
of the foetus. The fetal platelet antigens, which differ from those of the mother, are inherited 
from the father and elicit alloantibody production in the mother. Maternal alloantibodies can 
cross the placenta during pregnancy due to the haemochorial placenta in humans. NAIT can 
already occur during a first pregnancy in healthy mothers. Newborns display petechiae, purpura 
or haematoma, infrequently also visceral haemorrhages and in 20% of cases intracranial 
haemorrhages. A thrombocytopenia and sometimes anaemia due to haemorrhages can be found 
(Kaplan, 2006). 
Naturally occurring cases of neonatal isoerythrolysis (NI) or neonatal haemolytic disease have 
been observed in horses and cats. This feto-maternal incompatibility manifests itself post natum 
after colostral intake of maternal alloantibodies and is characterised by immune-mediated 
destruction of RBCs. In cats, this phenomenon is associated with the fading kitten syndrome 
(Bücheler, 1999). NI in horses is caused by alloimmunisation of the mare lacking specific 
erythrocyte antigens carried by the foal and inherited from its sire (Kähn et al., 1991). 
Alloimmunisation can occur during pregnancy, parturition or blood transfusions (Kähn et al., 
1991). 
A feto-maternal incompatibility phenomenon caused by vaccination had been observed in cattle 
in the past. Vaccines against anaplasmosis contained erythrocytic membranes, which stimulated 
alloantibody production in the vaccinated cow, if the cow had different erythrocyte antigens as 
contained in the vaccine. Alloantibodies were transferred to calves via colostrum and caused a 
haemolytic anaemia in calves that had inherited the respective erythrocyte antigens from the sire 
against which alloantibodies from the dam were directed (Luther et al., 1985). 
 
3.3 Previous Studies on the Aetiopathogenesis of BNP 
Differential diagnoses of haemorrhagic diathesis in cattle include inherited or acquired disorders. 
The latter include for example infections, drug and chemical exposures or immunological causes. 
After the emergence of BNP, all of these differential diagnoses were investigated, and most of the 
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disorders could be excluded as aetiological factors for BNP. A strong evidence for an immune-
mediated pathogenesis was obtained in several studies. An overview of all studies considering 
different factors causative for a haemorrhagic diathesis related to BNP is given hereafter. 
 
3.3.1 Infectious Agents 
In cattle, different pathogens may induce clinical symptoms similar to those of BNP. Therefore, 
first studies on BNP considered potential infectious agents to be involved in the pathogenesis of 
BNP, since many BNP-calves also revealed therapy-resistant fever, which is frequently associated 
with viral infections (Friedrich et al., 2009c). 
Infections with the BVD virus cause a variable outcome in cattle, dependent on age and immune 
status of the animal, as well as on the strain and biotype of the virus (Lanyon et al., 2014). One of 
these disease syndromes is the haemorrhagic syndrome in calves, which is an acute infection 
caused by noncytopathic (ncp) BVD virus (Liebler et al., 1995). In an experimental study, young 
calves were infected with a ncp field isolate of the BVD virus and clinical signs similar to those 
observed in BNP, e.g. internal and external haemorrhages and a thrombocytopenia, were 
detected 2 weeks post infectionem (Corapi et al., 1989). Bone marrow biopsies, however, showed 
a marked hyperplasia of the megakaryocytes (Corapi et al., 1989). This is in contrast to findings in 
BNP-calves, which revealed a damage of the bone marrow related to all cell lineages including the 
megakaryocytes (Bell et al., 2010b; Friedrich et al., 2009c; Kappe et al., 2010; Pardon et al., 2010; 
Schröter et al., 2011). Without exception, RT-PCRs for BVD antigen were negative in all tested 
BNP-calves (Bell et al., 2010b; Buck et al., 2011; Friedrich et al., 2009c; Friedrich et al., 2011; 
Kappe et al., 2010; Krappmann et al., 2011; Pardon et al., 2010). Moreover, all dams of affected 
calves had been vaccinated against BVDV (Friedrich et al., 2009c; Pardon et al., 2010; Schröter et 
al., 2011). In challenge studies, no BVDV-antibodies were detected before colostrum intake, but 
after colostrum ingestion, calves were positive for BVDV-antibodies (Friedrich et al., 2011; 
Schröter et al., 2011). Calves that did not survive BNP had significantly higher BVDV-antibody 
titres compared to animals that survived the disease (Schröter et al., 2011). 
Bluetongue virus (BTV), or the epizootic haemorrhagic disease virus (EHDV), may cause clinical 
signs like reddening of the lip mucosa, oral erosions, petechiae on the lingual and buccal papillae, 
or echymotic haemorrhages at the hoof (Brenner et al., 2011; Yadin et al., 2008). PCRs for both 
BTV (Buck et al., 2011; Kappe et al., 2010; Klemt, 2010; Krappmann et al., 2011; Pardon et al., 
2010) and EHDV (Pardon et al., 2010) antigens were negative in BNP-calves. In 2008, a vaccination 
against the bluetongue virus (BTV) type 8 had been introduced in Germany, and there were 
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concerns from farmers about a possible correlation between the respective vaccine and the 
occurrence of BNP (Kappe et al., 2010). However, BNP-cases had already been observed in 2007 
(Buck et al., 2011; Kappe et al., 2010; Krappmann et al., 2011). 
Kappe et al. (Kappe et al., 2010) detected circoviral DNA with very high similarity to the porcine 
circovirus type 2b (PCV-2) in five of 25 examined BNP-calves and in one of eight non-BNP-calves. 
In pigs, this virus is associated with a number of different syndromes like the postweaning 
multisystemic wasting syndrome (PMWS) or the porcine dermatitis and nephropathy syndrome 
(PDNS) (Segalés et al., 2005). Many years before the occurrence of BNP, this virus had already 
been described in Canadian cattle with respiratory distress or aborted bovine foetuses (Nayar et 
al., 1999). In other countries, such as the USA, PCV-2 had also been detected in cattle, whilst the 
exact biological impact of this virus in cattle is not understood until today (Li et al., 2011). Other 
studies did not find any evidence that PCV-2 is involved in the pathogenesis of BNP (Bastian et al., 
2011; Schröter et al., 2011; Willoughby et al., 2010). 
Friedrich et al. (Friedrich et al., 2009c) and Pardon et al. (Pardon et al., 2010) discussed a possible 
involvement of bovine parvovirus in BNP. In cats and dogs, this virus is known to cause either a 
panleucopenia or a pancytopenia (Hosokawa et al., 1987; Weiss et al., 1999). In cattle, the 
respective virus causes mainly diarrhoea, but no damage of the bone marrow (Durham et al., 
1985; Friedrich et al., 2009c). Moreover, no signs of a parvovirus infection were seen in histology 
in BNP-calves (Pardon et al., 2010). 
Pathogenic bacteria were also included in analyses. A wide range of different bacteria was 
detected in BNP-calves, but none of them were found in all BNP-calves and were therefore 
associated with BNP (Kappe et al., 2010; Klemt, 2010; Krappmann et al., 2011). Pasteurella 
multocida, which is associated with a haemorrhagic septicaemia (Rhoades et al., 1967), was only 
found sporadically (Kappe et al., 2010) and no Salmonella spp. was detected (Schröter et al., 
2011). 
 
3.3.2 Toxicological Agents 
In literature, several toxicological agents are described, which may cause bone marrow damages 
and clinical signs as observed in BNP. 
Furazolidone is a nitrofuran antibiotic and can cause a depletion of the bone marrow and similar 
clinical symptoms as BNP, but only after administration over a long period of time (Hofmann, 
1972). Nitrofuranes are forbidden by law for the use in food producing animals in the European 
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Union (Commission Regulation (EU) No 37 / 2010). Additionally, BNP-calves tested for 
furazolidone were all negative (Friedrich et al., 2009c; Kappe et al., 2010). Similarly, 
chloramphenicol can cause an aplastic anaemia in cattle (Jorna and Postema, 1986), but is also 
forbidden by law for food producing animals in the European Union (Commission Regulation (EU) 
No 37 / 2010). Overdosage of the coccidiostat halofuginone can cause bloody diarrhoea 
(Scholtysik and Steuber, 2007). This pharmaceutical was not applied in all monitored BNP-affected 
herds (Pardon et al., 2010), and no indication was obtained for overdosage of halofuginone in 
BNP-calves (Krappmann et al., 2011). Other pharmaceuticals that may cause BNP-associated 
symptoms are sulfonamides or non-steroidal anti-inflammatory drugs. However, these drugs were 
applied only occasionally in connection with the treatment of BNP, and an association of these 
drugs with BNP was excluded by Friedrich et al. (Friedrich et al., 2009c). 
S-(1,2-Dichlorovinyl)-L-cysteine (DCVC) is a metabolite of trichloroethylene, which has been used 
in the past for the extraction of soybean oil (Kappe et al., 2010). Intoxications with this agent can 
cause aplastic anaemia and renal injury (Lock et al., 1996). However, no DCVC could be detected 
in BNP-calves (Friedrich et al., 2009c; Kappe et al., 2010). 
Bracken fern or field melilot were excluded as potential toxic agents involved in BNP, too (Bell et 
al., 2010b; Friedrich et al., 2009c; Kappe et al., 2010; Pardon et al., 2010; Sauter-Louis et al., 
2012). 
Analyses for mycotoxins, such as trichothecenes or mycotoxins of Stachybotrys chartarum and 
Aflatoxin B1 in forage samples, were also negative in BNP-calves (Buck et al., 2011; Friedrich et al., 
2009c; Kappe et al., 2010; Pardon et al., 2010). 
In an epidemiological questionnaire, a couple of farms affected by BNP as well as a few control 
farms could not exclude the use of rodenticides (Sauter-Louis et al., 2012). The study indicated 
that dicumarol was used in most instances (Sauter-Louis et al., 2012), which does not cause bone 
marrow depletion (Runciman et al., 2002; Sauter-Louis et al., 2012; Wang et al., 2007). 
 
3.3.3 Genetic Factors 
Studies on the aetiology of BNP also involved investigations on possible genetic factors associated 
with BNP. Several cattle breeds were affected by BNP (Bell et al., 2009; Corbière et al., 2009; 
Friedrich et al., 2009c; Pardon et al., 2010), but only a small proportion of calves showed clinical 
signs of BNP compared to the respective whole cattle population. This was also true on individual 
farm level, where animals were kept under the same conditions (Foucras et al., 2011; Kasonta et 
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al., 2012; Pardon et al., 2010; Reichmann, 2012; Witt et al., 2011). Some dams gave birth to more 
than one BNP-calf (Pardon et al., 2010), and in challenge studies, the disease could be reproduced 
with colostrum from specific dams in several unrelated challenge calves (Friedrich et al., 2011; 
Schröter et al., 2012), indicating that the production of the aetiological agent may be restricted to 
a certain subset of dams. 
For hereditary coagulopathies in cattle, inherited disorders involving coagulation factor VIII (Khalaj 
et al., 2009) or a factor XI deficiency in Holstein cattle (Marron et al., 2004) have been described. 
Krappmann et al. (Krappmann et al., 2011) screened a well characterised crossbreed Holstein x 
Charolais cattle resource population with incidence of clinical BNP for mutations in factor XI. No 
specific mutations in the coagulation factor XI gene associated with BNP could be detected. 
However, the study revealed that all clinical BNP-cases were confined to one specific sire line of 
the F2 resource population. All affected BNP-calves were progeny of a single F1 Charolais x 
Holstein crossbred male. This accumulation of clinical BNP-cases in one specific family was 
statistically significant. Therefore, a genetic predisposition involved in BNP-pathogenesis is likely 
(Krappmann et al., 2011). 
A further study genotyped BNP-calves and control animals of the Holstein breed at the major 
histocompatibility complex (MHC) class II DRB3 locus (Ballingall et al., 2011), which is associated 
with autoimmune diseases and variations in immune response (Handunnetthi et al., 2010). No 
significant differences in allele frequencies were found in BNP-calves compared to control animals 
(Ballingall et al., 2011). 
 
3.3.4 Idiopathic Cases of Haemorrhagic Diathesis 
Sporadic cases similar to BNP and unknown aetiology were observed before the accumulation of 
BNP-cases in 2007 (Friedrich et al., 2009c). A recently published epidemiological study revealed 
that 4.5% of suspected BNP-cases were born to non-PregSure® BVD-vaccinated dams, received 
colostrum exclusively from the own dam, and originated from farms with no history of BNP-cases. 
However, these calves were not further investigated for other factors that might contribute to a 
pancytopenia (Jones et al., 2013). In literature, there are only rare reports on idiopathic 
haemorrhagic diathesis in calves. 
Ammann et al. (Ammann et al., 1996) described the case of a 14-day-old Holstein calf that 
displayed clinical signs of a haemorrhagic disorder like a bloody diarrhoea. This calf had been 
treated with trimethroprim and sulfadoxine. Haematology revealed a severe anaemia, leucopenia 
and thrombocytopenia, while gross pathology revealed multiple haemorrhages. These findings 
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were all associated with a hypocellular bone marrow, which was demonstrated in a histological 
examination. As possible aetiology for the condition in this calf, a drug-induced or inherited bone 
marrow aplasia was suspected. 
Another case report was documented in 2007 in Japan (Shimada et al., 2007). This case report 
describes an 11-day old Holstein calf, which was presented with melaena, external haemorrhages 
and pancytopenia, including a non-regenerative anaemia. In histology, a bone marrow hypoplasia 
was diagnosed, which comprised all cell lineages. Possible causes for the bone marrow aplasia, 
e.g. genetic factors, viral infections such as BVDV, toxic agents, chemicals or radiation were 
excluded. The calf had received no drugs associated with a bone marrow aplasia (Shimada et al., 
2007). Neither the vaccination history of the dam was mentioned in this case report, nor was the 
BVDV status of the dam known. This case report has a strong resemblance to BNP and a possible 
association of this case with BNP remains unclear. 
A similar case report was published shortly afterwards, describing a 15 day old Japanese black calf 
with clinical findings similar to those of BNP (Fukunaka et al., 2010). Haematological findings 
included a severe thrombocytopenia and leucopenia as well as a non-regenerative anaemia. 
Multiple haemorrhages were detected in necropsy, and histopathology revealed a marked bone 
marrow aplasia. Toxins or infections in utero were considered as unlikely and a viral infection with 
BVDV was ruled out (Fukunaka et al., 2010). The authors could not exclude a possible association 
with BNP. 
 
3.3.5 Evidence for an Alloimmune-mediated Pathogenesis of BNP 
First investigations on the aetiopathogenesis of BNP observed that some dams gave birth to more 
than one BNP-calf, although not always in consecutive years (Friedrich et al., 2011; Pardon et al., 
2010). Based on observations from farmers and findings of an emerging thrombocytopenia after 
colostrum intake in BNP-calves, and given the time period between colostrum ingestion and the 
development of clinical signs of BNP, it was suspected that colostrum might be involved as a 
potential aetiological agent in the pathogenesis of BNP (Friedrich et al., 2011). In challenge 
experiments, colostrum from specific dams, which all had been vaccinated with PregSure® BVD, 
was then confirmed to be the key aetiological agent involved in the pathogenesis of BNP. Clinical 
BNP or at least haematological changes could be reproduced quite reliably in the majority of 
challenge calves originating from different breeds by feeding colostrum from unrelated dams that 
had given birth to a BNP-calf before (Friedrich et al., 2011; Schröter et al., 2011). These results 
pointed to an immune-mediated mechanism, putatively elicited by antibodies in colostrum 
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(Friedrich et al., 2011). A different approach to demonstrate an alloimmune-mediated mechanism 
was described by Foucras et al. (Foucras et al., 2011). In this experiment, a pool of IgGs from 
dams, which had given birth to a BNP-calf before, was injected i.v. into unrelated neonatal healthy 
calves, thereby excluding a potential effect of antibody resorption in the digestive tract after 
colostrum intake. Accordingly, characteristic findings associated with BNP were observed in these 
calves, including a cellular depletion of the bone marrow. 
Further evidence of an alloimmune-mediated mechanism was then revealed in other studies. 
Pardon et al. (Pardon et al., 2011) and Bridger et al. (Bridger et al., 2011) demonstrated via flow 
cytometry that sera from BNP-dams contained alloantibodies that bind to calf leucocytes. The 
binding of alloantibodies was not age-dependent, since also older calves showed reactivity, and 
therefore the expression of the target antigen(s) does not seem to be age-related (Pardon et al., 
2011). The disease is, however, restricted to neonates after colostrum ingestion, because 
colostral alloantibodies are only able to pass the intestinal barrier up to 36 hours p.c.i. (Kruse, 
1983). Additionally, in contrast to other species like humans, antibodies in cattle are not able to 
pass from the mother to the fetus during gravidity due to the epitheliochorial nature of the 
placenta (Bridger et al., 2011; Kruse, 1983; Pardon et al., 2011). In a further experiment, the 
amount of alloantibody-positive lymphocytes/monocytes (IgG+-cells) in neonatal calves was 
monitored after intake of colostrum from BNP-dams. The percentage of IgG+-cells mainly 
increased between 6 - 12 hours post colostrum intake and thereafter the severity of clinical signs 
of BNP correlated with the percentage of IgG+-cells and the duration and persistence of these 
levels (Bridger et al., 2011). Cells that were opsonised with alloantibodies induced 
cytophagocytosis by macrophages (Bastian et al., 2011). 
No alloantibodies were bound when incubating leucocytes with either serum of non-BVD-
vaccinated dams or with serum from dams which had been vaccinated with an alternative BVD-
vaccine to PregSure® BVD (Bastian et al., 2011). Accordingly, alloantibody titres in BNP-dams were 
found to be significantly higher than in BVDV-unvaccinated control dams and also correlated with 
the severity of BNP in calves (Bridger et al., 2011). The severity of BNP, however, did not correlate 
with the BVDV-antibody titres in these dams (Bridger et al., 2011), although it had been shown 
that BVDV-neutralising antibody titres of BNP-dams exceeded those of PregSure® BVD vaccinated 
non-BNP-dams (Bastian et al., 2011). Three repetitive immunisations with PregSure® BVD had 
been shown to induce high alloantibody titres, which differed significantly from alloantibody titres 
found in animals immunised with other booster vaccination schemes like three consecutive 
vaccinations with an inactivated BVD vaccine other than PregSure® BVD. Applying a “modified 
two-step vaccination” that consisted of a primary vaccination with PregSure® BVD and two 
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subsequent booster immunisations with a live attenuated BVD vaccine also resulted in 
significantly lower alloantibody titres than a vaccination scheme using only PregSure® BVD 
(Kasonta et al., 2012). 
When testing a panel of BNP-sera for alloantibody-binding to leucocytes of different individuals, 
leucocytes of one individual did not necessarily show a reaction with each of the BNP-dam sera 
(Bastian et al., 2011; Bridger et al., 2011). This may indicate that individual BNP-dams responded 
to different antigens (or different alleles of a polymorphic antigen), but also that expression of 
alloantigens was variable among individuals (Bastian et al., 2011). 
Furthermore, immunofluorescence microscopy of peripheral blood smears and bone marrow 
smears revealed that in comparison to non-BNP-dams, the sera of BNP-dams contained 
alloantibodies that bound to these cells. However, the megakaryocytes did not show a distinct 
staining when incubated with BNP-dam sera in this study (Pardon et al., 2011). In flow cytometry 
studies, it was observed that BNP-associated alloantibodies bound more effectively to 
lymphocytes and monocytes compared to granulocytes (Bastian et al., 2011; Bridger et al., 2011; 
Pardon et al., 2011). These binding patterns of BNP-associated alloantibodies to peripheral blood 
cell subsets were evaluated in a further study via immunofluorescence microscopy of different 
cell types with either BNP-dam or non-BNP-dam colostrum (Assad et al., 2012). Firstly, it was 
shown that BNP-alloantibodies bound to 100% of all platelets and to 70% of all leucocytes. Cells of 
the myeloid lineage, like granulocytes and monocytes, displayed 100% reactivity with 
alloantibodies, whilst not all cells of the lymphoid lineage, especially the CD4+ T cells (T-helper 
cells), bound BNP-associated alloantibodies. Secondly, regardless of breed, the reactivity of 
colostral alloantibodies was identical for cells either of juvenile or of adult origin, pointing to a 
constant expression of the target antigen (Assad et al., 2012). 
The binding pattern of BNP-associated alloantibodies was also evaluated with the BVD virus and 
different cell lines used for vaccine production. No reaction of alloantibodies could be detected 
with the BVD-virus or surface antigens of all cell lines, except for the bovine kidney cell line used 
for the production of PregSure® BVD (Bastian et al., 2011). In order to evaluate if the induction of 
alloantibodies was restricted only to PregSure® BVD, guinea pigs were immunised with different 
BVD-vaccines and only PregSure® BVD induced alloantibodies that bound to cell surface antigens 
of bovine leucocytes (Bastian et al., 2011). 
Two independent studies proposed that BNP-associated alloantibodies target the MHC class I 
antigen present on bovine leucocytes, but also on the Madin-Darby bovine kidney cell line (MDBK) 
used for the production of the inactivated vaccine PregSure® BVD (Deutskens et al., 2011; Foucras 
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et al., 2011). MHC class I, an approximately 42 kDa protein, from the MDBK cell line was shown to 
be a constituent and therefore a contamination of PregSure® BVD, which might have elicited 
alloantibody production in BNP-dams (Deutskens et al., 2011; Foucras et al., 2011). After down-
regulation of ß2-microglobulin-coding mRNA in MDBK cells via RNA interference and consecutively 
reduced MHC class I expression, cell staining was reduced after incubation with BNP-dam sera 
(Foucras et al., 2011). Immunoprecipitation with BNP-dam sera showed a reaction with MHC class 
I on the MDBK cell line (Deutskens et al., 2011; Foucras et al., 2011; Kasonta et al., 2012). Sera of 
non-vaccinated BVDV-free dams or dams which had been vaccinated with an alternative 
inactivated BVD vaccine revealed no or only a very weak reactivity with MHC class I, respectively. 
However, some of the PregSure® BVD-vaccinated non-BNP-dams also showed reactivity with MHC 
class I (Deutskens et al., 2011). This was confirmed by Kasonta et al. (Kasonta et al., 2012) for the 
serum of a large proportion of animals after experimental vaccination with PregSure® BVD. 
Additionally, after incubation with a standardised, pooled BNP-serum, a reactivity with MHC class 
I on PBMCs of some BNP-dams was revealed (Deutskens, 2012). 
Evidence of a massive cellular contamination of PregSure® BVD was obtained in a further study 
(Euler et al., 2013) that compared the cell surface proteome of the MDBK cell line with the protein 
composition of PregSure® BVD. PregSure® BVD contained a 3.5 fold higher amount of proteins 
than a different, live-attenuated BVD-vaccine. Several proteins were shared between PregSure® 
BVD and the MDBK cell surface. MHC I was, however, one of the least abundant shared proteins 
in PregSure® BVD and MDBK cells and the authors instead presented some other alloantigens as 
candidates, that still need further validation (Euler et al., 2013). 
 
3.4 RNA-Sequencing (RNA-Seq) 
In recent years, next-generation sequencing (NGS) or deep-sequencing technologies have been 
introduced, which offer the opportunity for high throughput sequencing at single-base resolution. 
In case of transcriptome sequencing, the method is termed RNA-Seq (RNA sequencing). This novel 
method was applied in our second study and therefore, a short overview on advantages of this 
method will be given.  
The transcriptome is defined as the sum of all RNA molecules or transcribed loci, including mRNA, 
tRNA, rRNA and non-coding RNA, in a cell or particular tissues at a specific time point or condition. 
RNA-Seq provides the option of mapping and quantifying transcriptomes. It is not restricted to an 
existing genome annotation of a species. Hence, also novel transcripts or genes can be detected. 
This method can also reveal exon/intron boundaries or alternative splicing. Additionally, sequence 
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variations, for example single nucleotide polymorphisms (SNPs), can be evaluated with RNA-Seq 
(Lister et al., 2009; Wang et al., 2009). Another advantage of RNA-Seq in comparison to 
microarrays is its large dynamic range. Therefore, transcripts with very high or low expression 
levels or marked fold-changes can be detected. Finally, this method is characterised by a low 
technical variance. Results for both technical as well as biological replicates can be reproduced 
reliably (Wang et al., 2009). 
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4 Objectives 
Several questions regarding the aetiopathogenesis of BNP still remain open, and some published 
results demand further research. For this thesis, two main aspects concerning aetiopathogenesis 
and manifestations of BNP were selected for further evaluation. 
In literature, several field observations or challenge studies reported on the incidence of 
subclinical BNP-cases. Subclinical BNP-calves display no clinical signs of BNP, but a shift in cell 
counts below the applied reference ranges in at least two haematopoietic cell lineages (Friedrich 
et al., 2011; Pardon et al., 2010; Schröter et al., 2011; Witt et al., 2011). The true incidence of 
subclinical BNP-cases has, however, not been thoroughly investigated. An accumulation of clinical 
BNP-cases in exclusively one specific sire line of an F2 experimental resource population was 
revealed in a previously performed study at our institute (Krappmann et al., 2011). All BNP-calves 
were descendants of one F1 male. Hence, the hypothesis of a genetic predisposition being 
involved in clinical BNP was proposed (Krappmann et al., 2011). Therefore, the present study 
investigated the incidence, a possible genetic predisposition, and further epidemiological factors 
involved in subclinical BNP (Publication I). 
The occurrence of BNP is strongly associated with the vaccination of dams with a specific 
inactivated vaccine (PregSure® BVD) against the Bovine Viral Diarrhoea Virus (BVDV) (Lambton et 
al., 2012; Sauter-Louis et al., 2012). This vaccine has been shown to induce very high antibody 
titres against BVDV (Bastian et al., 2011; Raue et al., 2011), but also to elicit the production of 
alloantibodies in some dams (Bridger et al., 2011; Pardon et al., 2011). The vaccine comprises a 
unique adjuvant. Furthermore, it has been revealed that the vaccine is highly contaminated with 
proteins derived from the Madin-Darby bovine kidney (MDBK) cell line used for the production of 
the specific vaccine (Euler et al., 2013). Due to these particular characteristics of the vaccine, the 
second aim of the present study was to characterise the immune response to vaccination with 
PregSure® BVD to gain insight into the structural and quantitative regulation of the blood 
transcriptome by means of an RNA-Seq approach (Publication II). 
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5 Results 
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6 Discussion 
Since the emergence of BNP in 2007, several studies focussed on different factors potentially 
involved in the aetiopathogenesis of the disease. Although these studies remarkably shed light 
onto the complex aetiopathogenesis of this alloimmune disease, a number of questions regarding 
the pathogenesis require further investigation or have emerged from published findings. The 
fundamentals for the objectives deduced for this study were limited data concerning subclinical 
BNP cases (Pardon et al., 2010; Witt et al., 2011) and the hypothesis of a genetic predisposition 
involved in clinical BNP (Krappmann et al., 2011). Furthermore, the immune response to 
vaccination with the specific inactivated BVD-vaccine associated to BNP (PregSure® BVD) had not 
been characterised in detail before. It was only known that this vaccine elicited significantly 
higher neutralising antibody titres compared to other commercial BVD-vaccines (Bastian et al., 
2011; Raue et al., 2011), and additionally evoked BNP-associated pathogenic alloantibodies 
(Bridger et al., 2011; Pardon et al., 2011). Results from our studies confirm that a genetic 
predisposition is required for clinical and potentially subclinical BNP, and provide evidence that 
the incidence of subclinical BNP cases is not higher than for clinical BNP cases. Analysis of the 
blood transcriptome regulation after booster vaccination with PregSure® BVD applying an RNA-
Seq approach revealed a very coordinated immune response to double-stranded (ds) RNA, 
although the inactivated vaccine is directed against a single-stranded (ss) RNA virus. This indicates 
a contamination of the vaccine with dsRNA, or the inclusion of a dsRNA analogue into the vaccine. 
Additionally, the study identified a novel gene with cytokine-like features, which is highly 
upregulated after vaccination in all animals. These results are comprehensively discussed 
hereafter in the context of the aetiopathogenesis of BNP. 
All our studies were performed on animals of the experimental German Holstein x Charolais 
crossbred resource population at the FBN Dummerstorf, except for one German Holstein cow also 
kept within the resource population. This resource population provided a good basis for the 
investigations, because this population had been kept throughout under constant housing, 
feeding and management conditions including identical vaccination protocols for all cows. All 
dams had received at least a basic vaccination with PregSure® BVD, consisting of two doses given 
according to the manufacturer’s instructions. Booster vaccinations were performed annually. 
PregSure® BVD presents the main risk factor for producing BNP colostrum (Lambton et al., 2012; 
Sauter-Louis et al., 2012), and the respective vaccination regime is known to induce high 
alloantibody titres (Kasonta et al., 2012). All dams included in the second study (Demasius et al., 
2013) had been classified into three groups according to results previously reported by 
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Krappmann et al. (Krappmann et al., 2011) and according to findings of our first study (Demasius 
et al., 2014). Firstly, dams, which gave birth to clinical BNP-calves, were included. They all 
originated, except for the German Holstein cow, from one specific sire line and were fullsibs. The 
second group comprised fullsib-dams from the same sire line which in contrast had given birth to 
clinically healthy calves, but which nonetheless showed haematological deviations from the 
average of the peer group. Thirdly, a group of control cows from alternative sire lines and with 
healthy calves was included. 
Our first study (Demasius et al., 2014) closely monitored all newborn calves of the resource 
population for the incidence of subclinical BNP and other epidemiological factors involved in 
clinical and subclinical BNP. Other studies which had reported on the incidence of subclinical BNP 
(Pardon et al., 2010; Witt et al., 2011) considered calves with haematological alterations and 
without clinical signs as suspected subclinical cases after only a single blood sampling. Although 
literature on haematological profiles of neonatal calves is sparse, reports on healthy calves show 
that they may display transient blood cell counts below reference ranges (Egli and Blum, 1998). 
Similar findings were also reported from BNP challenge studies (Friedrich et al., 2011; Schröter et 
al., 2011). The very close and frequent clinical and haematological monitoring of a subset of 
calves included in our study enabled exact classification of subclinical cases and discrimination of 
subclinical BNP-calves from healthy calves that showed only transient thrombocytopenia or 
leucopenia. Moreover, all calves included in our study had received colostrum exclusively from 
their own dams, since feeding of mixed colostrum on BNP-affected farms may result in an 
increased risk for calves to develop haematological alterations (Witt et al., 2011). Our study could 
not confirm the hypothesis that subclinical BNP cases occur more frequently than clinical BNP 
cases. However, the single observed subclinical BNP case in our study occurred in the one specific 
sire line of the resource population in which an accumulation of clinical BNP cases had been 
observed in a previous study (Krappmann et al., 2011). This previous study had proposed the 
hypothesis of a possible genetic predisposition involved in clinical BNP (Krappmann et al., 2011). 
The present study could confirm this hypothesis of a genetic predisposition involved in clinical 
BNP, as two further clinical BNP cases exclusively occurred in this one specific sire line. For the 
single subclinical BNP case, a genetic predisposition can also be assumed, as this case was also 
confined to the BNP-affected sire line. Moreover, healthy calves of this BNP-affected sire line 
revealed a decrease in thrombocytes between day 7 and day 14 after colostral intake and 
significantly decreased thrombocyte counts on day 14 as well as decreased leucocyte counts on 
day 7, compared to healthy calves of other sire lines. Although blood cell counts were still above 
ranges reported for young calves in other studies (Mohri et al., 2007), these calves must have 
ingested an agent via colostrum which had a decreasing effect on cell numbers of certain blood 
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cell lineages. Considering published literature on BNP, it can only be speculated about the 
factor(s) responsible for different manifestations of the disease at this stage. These factors could 
be variable alloantibody titres in dams, different types of alloantibodies produced by dams and 
different alloantibody combinations ingested by calves, or also a predisposition on the part of the 
calves. Yet, our results suggest a genetically determined reaction of the dam towards PregSure® 
BVD vaccination. Our study indicates that subclinical BNP occurs with a low incidence. For 
confirmation of this hypothesis, large scale studies with close clinical and haematological 
monitoring should be performed in different cattle herds vaccinated with PregSure® BVD. But 
since a genetic predisposition also seems to be involved in subclinical BNP, the true incidence for 
subclinical BNP might be similarly low as for clinical BNP. This would be in agreement with the 
reported low incidence for clinical BNP (Kasonta et al., 2012; Pardon et al., 2010) relative to the 
number of PregSure® BVD-vaccinated animals or the number of vaccination doses sold (Kasonta 
et al., 2012). Knowledge about the true incidence of subclinical BNP is useful, because subclinical 
BNP might result in a decrease of health statuses of calves (Sauter-Louis et al., 2012). On farms 
with high incidence rates of BNP, subclinical cases were assumed to be the reason for an increase 
in medical treatments (Reichmann, 2012), which can result in substantial economic losses. 
Our study did not reveal further epidemiological factors contributing to BNP. With regard to 
PregSure® BVD vaccinations, neither the time point itself nor the proximity to parturition were 
risk factors for clinical or haematological alterations associated with BNP. These results are in line 
with findings of other epidemiological studies (Jones et al., 2013; Lambton et al., 2012). Also, the 
frequency of PregSure® BVD vaccination did not present a risk factor, which was also shown by 
Lambton et al. (Lambton et al., 2012). However, the findings of Lambton et al. (Lambton et al., 
2012) are in contrast to those of Jones et al. (Jones et al., 2013), the latter revealing that dams of 
second or more lactation were at higher risk of having a BNP-calf, because these dams had 
received more doses of PregSure® BVD compared to first lactation dams. Repetitive vaccinations 
with PregSure® BVD result in higher alloantibody titres (Kasonta et al., 2012). However, 
experiments also showed that some animals already developed alloantibodies after receiving only 
a single dose of PregSure® BVD (Kasonta et al., 2012). Finally, different vaccination regimes may 
also account for differing alloantibody titres in dams (Kasonta et al., 2012). Our study applied for 
all cows an identical PregSure® BVD vaccination scheme according to the manufacturer’s 
instructions, which had been reported to result in higher alloantibody titres compared to a two-
step vaccination regime (Kasonta et al., 2012). Excluding further potential epidemiological factors 
for BNP in the experimental resource population of the FBN Dummerstorf focuses factors 
involved in the aetiopathogenesis of BNP to a genetic predisposition of the dam required for 
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producing BNP-colostrum (Demasius et al., 2014; Krappmann et al., 2011) in combination with the 
main risk factor, PregSure® BVD vaccination (Lambton et al., 2012; Sauter-Louis et al., 2012). 
Reports that contaminating MHC class I antigen, originating from the MDBK cell line used for 
vaccine production of PregSure® BVD, is responsible for production of pathogenic alloantibodies 
in some dams (Deutskens et al., 2011; Foucras et al., 2011) would match with the hypothesis of a 
possible genetic predisposition required for producing BNP-colostrum (Demasius et al., 2014; 
Krappmann et al., 2011). Related dams, as found in our experimental setup, are more likely to 
display the same MHC class I haplotypes. Dams that differ in MHC class I genotype from the MHC 
class I genotype of the MDBK cell line will respond to the MHC class I antigen with alloantibody 
production. The low incidence rate observed for clinical BNP-calves (Kasonta et al., 2012; Pardon 
et al., 2010) might therefore be explained by diversity in the MHC class I region (Kelley et al., 
2005), and the genetically determined MHC class I makeup carried by dam and calf. However, 
considering different strategies that exist to achieve and maintain diversity in the MHC region, 
and especially those applied in cattle, the MHC class I hypothesis has to be questioned. The 
strategies for maintaining diversity in the MHC class I region include polymorphic genes and/or 
varying gene numbers and combinations in different haplotypes (Kelley et al., 2005; Parham et al., 
1995; Trowsdale and Parham, 2004). Cattle apply a combination of both strategies. So far, the 
existence of six classical MHC class I genes (gene 1 – 6) has been proposed (Hammond et al., 
2012). Cattle show region configuration polymorphism, expressing between one and three of the 
six genes per haplotype (Birch et al., 2006; Codner et al., 2012; Ellis et al., 1999). Additionally, high 
degrees of polymorphisms can be found between individuals (Babiuk et al., 2007). Considering 
these strategies applied by cattle for maintaining diversity in the MHC class I region, it is unlikely 
that the large proportion of observed non-BNP-dams shared (an) MHC class I allele(s) with the 
MDBK cell line. This assumption is underlined by findings that alloantibodies against MHC class I 
can be found in sera of some non-BNP-dams (Deutskens et al., 2011) as well as in a large 
proportion of animals after experimental vaccination (Kasonta et al., 2012). The high degree of 
diversity in the MHC class I also contradicts the hypothesis of causal MHC class I alleles, because 
clinical BNP or at least haematological alterations could be reproduced frequently with BNP-
colostrum in almost all challenge calves (Bell et al., 2013; Friedrich et al., 2011; Schröter et al., 
2011). It is unlikely that all of these unrelated challenge calves shared MHC class I alleles with the 
MDBK cell line. In our resource population, sera of all dams included in the second study, 
regardless of BNP status, contained alloantibodies directed against MHC class I on MDBK cells 
(Deutskens, 2012). This also included the control cows from non-BNP affected sire lines. Calves of 
these dams which were monitored in our first study (Demasius et al., 2014) did not show any 
clinical or haematological alterations consistent with BNP. Our unpublished results have revealed 
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that these control cows, which were included in our second study, do not share classical MHC 
class I alleles with the MDBK cell line, except for one control cow, which shares a single MHC class 
I allele with the MDBK cell line. Consequently, also control dams differing from the MDBK cell 
MHC class I genotype might respond to allogeneic MHC class I of the MDBK cell line with 
alloantibody production. Exclusion of MHC class I as single causal agents for BNP would eradicate 
further puzzling observations regarding the MHC class I hypothesis that had previously arisen. 
These findings reported that BNP-associated alloantibodies bind to a target antigen expressed on 
platelets and all cells of the myeloid lineage, but not to all cells of the lymphoid lineage (Assad et 
al., 2012). However, MHC class I expression in humans is found on nearly all nucleated cells, and 
especially lymphoid tissues reveal high expression levels of MHC class I (Agrawal and Kishore, 
2000). If the ubiquitously expressed MHC class I would be the target antigen in calves, then 
alloantibody-related damages should not only be detected in haematological tissue in 
histopathology (Friedrich et al., 2009b; Pardon et al., 2010). As discussed in Euler et al. (Euler et 
al., 2013), a transfusion-related syndrome in humans, known as transfusion-related acute lung 
injury (TRALI), is characterised by a high frequency of MHC class I alloantibodies. However, these 
are only weak triggers with low fatality. Not all antigens crucial for transfusion have been 
identified yet (Euler et al., 2013). Prominent MHC class I alloantibody production in TRALI patients 
might overshadow other possible candidates, which might be the case in BNP as well (Euler et al., 
2013). 
Observations regarding challenge studies in calves suggest that potentially more than one antigen 
might induce BNP-associated alloantibody production. While feeding similar volumes of colostrum 
from a single BNP-dam to challenge calves resulted in different degrees of severity for clinical 
findings in these calves (Friedrich et al., 2011; Schröter et al., 2011), ingestion of mixed colostrum 
increased the incidence of clinical BNP as well as the mortality rate (Schröter et al., 2011). Feeding 
a standardised quantity from the same pooled colostrum to each challenge calf resulted in 
consistent alterations found in all challenge calves (Bell et al., 2013). If there are multiple causal 
antigens involved in BNP-associated alloantibody production, pooling colostrum increases the 
chance that a wider spectrum of different alloantibodies may be found in the colostrum as 
compared to colostrum of a single dam. It has to be considered, however, that if multiple 
alloantibodies would be directed against multiple different antigens, this will result in a dilution 
effect of each specific alloantibody in mixed colostrum and might not exert BNP in calves 
anymore. Indications for a massive contamination of PregSure® BVD with proteins derived from 
the MDBK cell line was revealed in the study by Euler et al. (Euler et al., 2013). Therefore, there is 
more than one potential protein candidate proposed which might elicit pathogenic alloantibody 
production. Results of our second study (Demasius et al., 2013) provided further evidence of a 
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massive contamination of the vaccine. We could observe a very coordinated immune response to 
dsRNA or a dsRNA analogue 14 days after booster vaccination with PregSure® BVD across all dams 
included in the study. This is revealed by upregulated, immune response-related genes and 
overrepresented pathways in KEGG (Kyoto Encyclopedia of Genes and Genomes, 
http://www.genome.jp/kegg/pathway.html) and Ingenuity pathway analysis (IPA, Ingenuity® 
Systems, http://www.ingenuity.com), especially by the RIG-I-like receptor signaling pathway 
(KEGG) and the string starting with the Toll-like receptor (TLR) 3 in the overrepresented canonical 
pathway TLR signaling pathway (IPA). TLR3 is a receptor for dsRNA (Zhang et al., 2013). Based on 
these results, we proposed a model for a very coordinated response to dsRNA after PregSure® 
BVD vaccination (Figure 5, (Demasius et al., 2013)). These results are striking, because PregSure® 
BVD is an inactivated vaccine against the BVDV, an ssRNA pestivirus belonging to the Flaviviridae 
(Peterhans et al., 2010). We could not identify differentially expressed genes or enriched 
pathways related to a response to ssRNA, for example upregulation of receptors for ssRNA like 
TLR7 or TLR8 (Heil et al., 2004). Since the vaccine is inactivated, there should not be viral 
replication occurring anymore. During replication, dsRNA may occur temporarily as a replication 
intermediate (Kato et al., 2006). Therefore, the source for dsRNA may have originated from the 
MDBK host cell line used for virus cultivation during vaccine production. This would be another 
proof of the massive contamination of the vaccine. Alternatively, a dsRNA analogue was added to 
PregSure® BVD, for example polyinosine-polycytidylic acid (poly(I:C)). Poly(I:C) can be detected by 
both RIG-1 as well as TLR3 (Kato et al., 2006). This synthetic dsRNA analogue has been shown to 
increase immunostimulatory effects (Thim et al., 2012) and could be an example for a potentially 
added adjuvant to PregSure® BVD. 
These findings also draw attention to the unique nanoparticle-based adjuvant contained in 
PregSure® BVD and to potentially further adjuvants added. According to the instruction leaflet, 
PregSure® BVD contains the adjuvants Quil A, cholesterol, Amphigen Base and drakeol 5 (liquid 
paraffin). Quil A is a saponin which originates from the bark of Quillaja saponaria, a Chilean tree 
(Singh and O'Hagan, 2003). This saponin has been shown to intercalate into cell membranes and 
to have haemolytic properties. To reduce these cytotoxic effects, Quil A is combined with 
phospholipids and cholesterol (Singh and O'Hagan, 2003). This results in nano-complex formation 
of about 40 nm, termed immune stimulatory complexes (ISCOMs), which carry the respective 
antigens (Sjölander et al., 1997). ISCOMs are recognised by APCs (Singh and O'Hagan, 2003). 
Adjuvants can have a major influence on the type of immune response elicited after vaccination 
(Sjölander et al., 1997). Quil A showed the ability to efficiently induce humoral and cell-mediated 
immune responses. In mice, antigen-specific antibodies of all IgG subclasses are induced. 
Additionally, Quil A induces both Th1-like as well as Th2-like immune responses, characterised by 
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IFN-γ and IL-4 production, respectively (Sjölander et al., 1997). The dose of the BVDV-antigen 
(structural glycoproteins E1 and E2, (Pfizer Animal Health Technical Bulletin, 2004)) bound to the 
ISCOM is not known. PregSure® BVD is known to elicit significantly higher neutralising antibody 
titres compared to other commercial BVD-vaccines (Bastian et al., 2011; Raue et al., 2011). These 
antibody titres even exceed titres observed in naturally infected animals (Bastian et al., 2011). It 
can be assumed that these findings are due to the very potent adjuvant contained in PregSure® 
BVD, which elicits multiple types of immune responses. Considering the aetiopathogenesis of BNP 
and the massive cellular contamination of the vaccine (Euler et al., 2013), it can be assumed that 
this potent adjuvant represents a further driving factor in alloantibody production towards an 
antigen, that has yet to be characterised. 
In our second study (Demasius et al., 2013), we found a strong upregulation of a previously 
unknown locus, XLOC_032517, with cytokine-like features, which was highly upregulated across 
all samples 14 days after booster vaccination with PregSure® BVD. No functional annotation of 
this locus could be found in cattle or any other species. Detection of this novel transcript 
highlights the capacity of RNA-Seq in comparison to other methods applied for transcriptome 
analysis (Wang et al., 2009). Whole blood samples of non-PregSure® BVD vaccinated animals also 
showed expression of XLOC_032517, however, at significantly lower levels compared to 
PregSure® BVD-vaccinated animals. In future studies, it has to be evaluated if upregulation of 
XLOC_032517 is specifically linked to PregSure® BVD vaccination, or can also be found after 
application of other immunostimulatory agents, for example after vaccination with other 
commercial BVD vaccines. Moreover, it should be determined which specific blood cells express 
XLOC_032517, and it should be determined, if the transcript is translated into a protein. Finally, it 
has to be evaluated, if expression of XLOC_032517 is specific to immune response in ruminants. 
Different immune response pathways and expression of specific cytokines are regulated by T-
helper cells (Th cells) (Kidd, 2003). Th1 cells elicit a cell mediated (CMIR) type 1 response to 
intracellular pathogens, while the type 2 response is an antibody mediated immune response 
(AMIR) to extracellular pathogens. In cattle, a type 2 response is associated with production of 
IgG1 (Estes and Brown, 2002). Colostrum-derived BNP alloantibodies were shown to be 
exclusively of IgG1 subclass (Assad et al., 2012). Several studies deal with AMIR or CMIR and could 
classify animals into high, average or low immune responders, accordingly (Begley et al., 2009; 
Heriazon et al., 2013; Hine et al., 2012). Besides these phenotypic classifications, heritabilities for 
both AMIR and CMIR have been established as moderate and high, respectively (Heriazon et al., 
2013). In our first study (Demasius et al., 2014), we could demonstrate an accumulation of BNP-
dams in one specific sire line of our resource population and a genetic predisposition required for 
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the production of pathogenic BNP-colostrum. It has been shown that some dams sporadically 
produce alloantibodies against MHC class I after only one dose of PregSure® BVD (Kasonta et al., 
2012), and that BNP-dams show higher alloantibody titres than non-BNP-dams (Bastian et al., 
2011). These findings suggest that these dams were high AMIR. A recent study that evaluated 
humoral immune response to human chorionic gonadotropin (hCG) in lactating dairy cows 
revealed that most cows showed a humoral immune response to hCG after two to three 
injections of hCG (Giordano et al., 2012). However, one cow already showed an antibody 
response against hCG after a single exposure, while some animals did not develop any detectable 
antibody responses after three injections of hCG (Giordano et al., 2012). Similar immune 
responses towards a contaminating antigen in PregSure® BVD can be assumed. Therefore, 
regardless of (a) further yet unidentified specific antigen(s) responsible for alloantibody 
production in BNP, genetically determined differences in humoral immune responses in dams 
vaccinated with PregSure® BVD have to be additionally considered regarding the 
aetiopathogenesis of BNP. 
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7 Conclusions and Outlook 
The emergence of the feto-maternal incompatibility phenomenon BNP in recent years and 
published results relating to the aetiopathogenesis of this disease have highlighted the risks 
involved in producing vaccines on homologous cell lines. In case of inadequate purification during 
vaccine production, contaminating antigens of the host cell line in combination with very potent 
adjuvants in the vaccine may result in fatal diseases as observed for BNP. Although PregSure® BVD 
has been retracted from the market and BNP will thus no longer occur, elucidation of the exact 
aetiopathogenesis of BNP is essential, because this may have implications for the general safety of 
vaccines, including vaccines for use in humans. Immunisation with specific vaccines and 
subsequent transcriptome analysis can give insights into the structural and quantitative regulation 
of the transcriptome in specific tissues or cells after vaccination. In our study the novel method of 
RNA-Seq on RNA derived from whole blood after booster vaccination with PregSure® BVD was 
applied. This represents an approach independent of any proposed hypotheses at a time where 
the exact aetiopathogenesis of BNP is not fully uncovered. Contradictory observations regarding 
the MHC hypothesis raise the question, if MHC class I should be regarded as a single causal 
antigen responsible for BNP-associated alloantibody production. It has been shown that 
PregSure® BVD is highly contaminated with proteins derived from the producer cell line MDBK, 
which implies that a whole panel of further potential antigens has to be validated in the future. 
We obtained indication on a previously postulated potential contamination of the vaccine with 
residues of the MDBK cell line, because we found a very coordinated immune response towards 
dsRNA after booster vaccination, although PregSure® BVD is directed against an ssRNA virus. 
Alternatively, a dsRNA analogue might have been added to the vaccine in order to improve the 
immunostimulatory properties of the vaccine. In addition, we could reveal a strong upregulation 
of a cytokine-like gene in all animals after booster vaccination with PregSure® BVD, which has 
never before been described in any other species. Prospective studies will have to evaluate 
whether this novel gene is specifically linked to an immune response after PregSure® BVD 
vaccination. Finally, we could confirm a genetic predisposition as a requirement for the 
production of either BNP- or non-BNP colostrum in dams vaccinated with PregSure® BVD.  
Based on these results and other findings regarding the aetiopathogenesis of BNP, future studies 
will have to consider genetically determined differential immune responses in cows after 
vaccination. Analyses for differential gene expression between BNP and non-BNP-dams after 
PregSure® BVD vaccination will give further insights into these mechanisms. Thereby, the very 
potent features of the unique adjuvant contained in PregSure® BVD and its potential effects have 
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to be kept in mind. Knowledge about expression patterns of antigens on haematopoietic stem 
cells and peripheral blood cells targeted by BNP-associated alloantibodies can also aid to the 
understanding of the aetiology of BNP. Finally, an exact description of MHC class I alleles 
expressed by BNP-dams, non-BNP-dams and the MDBK cell line will provide evidence, if MHC 
class I can be regarded as single causal agent for BNP-associated alloantibodies. Puzzling 
observations and published findings regarding the MHC hypothesis have highlighted that the 
exact aetiopathogenesis of BNP has not been fully elucidated yet.  
Summary 
 
58 
 
8 Summary 
 
Investigations on selected aspects involved in the aetiology of  
bovine neonatal pancytopenia (BNP) 
 
Bovine neonatal pancytopenia (BNP) is a recently emerged alloimmune disease affecting neonatal 
calves and is strongly associated with the vaccination of dams with a specific inactivated BVDV 
(Bovine Viral Diarrhoea Virus) vaccine (PregSure® BVD, Pfizer Animal Health). The vaccine 
comprises a unique adjuvant based on nanoparticles and has been shown to be highly 
contaminated with cellular proteins of the vaccine producer cell line MDBK (Madin-Darby bovine 
kidney). The disease is induced by ingestion of colostral alloantibodies of certain PregSure® BVD-
vaccinated dams. The hypothesis that BNP-associated alloantibodies might be directed against 
MHC class I has been proposed. Currently, there are published observations, which contradict this 
hypothesis and which suggest that the aetiopathogenesis of BNP has not been fully elucidated 
yet. The aims of this study were to gain more insights into selected factors and underlying 
mechanisms involved in BNP. The hypothesis of a genetic predisposition for clinical BNP had been 
proposed in a previous study, but the incidence and potential genetic predisposition for 
subclinical cases had not been investigated thoroughly before. Therefore, a well-defined cattle 
resource population was monitored for the incidence, vaccination-associated epidemiological 
factors and a possible genetic predisposition involved in subclinical BNP. Prominent immune 
responses to PregSure® BVD vaccination had been reported. This study characterised the immune 
response to a booster immunisation with PregSure® BVD to obtain insights into the structural and 
quantitative regulation of the blood transcriptome after vaccination by means of deep sequencing 
transcriptome analysis. Furthermore, this approach should facilitate insights into the composition 
of the vaccine. 
The previously proposed hypothesis of a genetic predisposition required for giving birth to clinical 
BNP-calves could be confirmed in this study. Our results suggest that a genetic predisposition is 
potentially also involved in subclinical BNP and additionally required for a significant decrease of 
thrombocytes and leucocytes in healthy calves without manifestation of clinical or subclinical 
BNP. In the monitored cattle resource population, the frequency of subclinical BNP did not exceed 
the frequency of clinical BNP-cases. Further vaccination-associated epidemiological factors, e.g. 
frequency of vaccination or time point of vaccination relative to parturition, could be excluded. 
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Transcriptome analysis 14 days after booster vaccination with PregSure® BVD highlighted a very 
coordinated immune response to double-stranded (ds) RNA, although the inactivated vaccine was 
directed against a single-stranded (ss) RNA BVD virus. The source of the dsRNA is unknown and 
could have originated from the MDBK cell line, which would underline the contamination of the 
vaccine with host cells from vaccine production. Alternatively, a dsRNA analogue was potentially 
added to improve the efficacy of the vaccine. Finally, this study identified a cytokine-like gene, 
which was highly upregulated across all animals after booster vaccination. This gene has not been 
described before in any other species. It has to be evaluated if upregulation of this gene is specific 
for ruminant immune response and linked to PregSure® BVD vaccination. In conclusion, this study 
confirmed that a genetic predisposition of PregSure® BVD-vaccinated dams is required for 
producing BNP-colostrum. Therefore, prospective studies will have to consider genetically 
determined differential immune responses between BNP- and non-BNP-dams towards exogenous 
proteins combined with very potent adjuvants. Regarding the MHC class I hypothesis, published 
observations raise the question, if MHC class I should be considered as single causal agent for 
BNP-associated alloantibodies. This requires further research. Potential allogeneic effects of a 
whole panel of contaminating proteins contained in the vaccine still have to be validated. 
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9 Zusammenfassung 
 
Untersuchungen zu ausgewählten Aspekten, die an der Ätiologie der  
Bovinen Neonatalen Panzytopenie (BNP) beteiligt sind 
 
Die Bovine Neonatale Panzytopenie (BNP) ist eine vor kurzem aufgetretene Alloimmunerkrankung 
neugeborener Kälber, die stark assoziiert ist mit der Impfung mit einer bestimmten, inaktivierten 
BVDV (Bovines Virusdiarrhoe-Virus) Vakzine (PregSure® BVD, Pfizer Animal Health) bei 
Muttertieren. Die Vakzine enthält ein spezifisches, auf Nanopartikeln basierendes Adjuvans. Es 
konnte nachgewiesen werden, dass der Impfstoff hochgradig mit zellulären Proteinen der MDBK-
Zellline (Madin-Darby bovine kidney) kontaminiert ist, die für die Impfstoffherstellung verwendet 
wurde. Die Erkrankung wird ausgelöst durch die Aufnahme kolostraler Alloantikörper bestimmter 
PregSure® BVD-geimpfter Muttertiere. Es ist die Hypothese aufgestellt worden, dass BNP-
assoziierte Alloantikörper gegen MHC Klasse I gerichtet sind. Gegenwärtig lassen sich publizierte 
Beobachtungen finden, die im Widerspruch zu der MHC Klasse I-Hypothese stehen und die zeigen, 
dass die Ätiopathogenese der BNP noch nicht vollständig geklärt ist. Ziele der vorliegenden Studie 
waren daher, weitere Einblicke in ausgewählte Faktoren und zugrunde liegende Mechanismen, 
die an der BNP beteiligt sind, zu gewinnen. In einer vorherigen Studie war die Hypothese einer 
möglichen genetischen Prädisposition für die klinische BNP aufgestellt worden. Über die Inzidenz 
und eine mögliche genetische Prädisposition für die subklinische BNP lagen noch keine 
umfassenden Studien vor. Daher wurde eine gut charakterisierte Ressourcenpopulation auf die 
Inzidenz, impfassoziierte epidemiologische Faktoren und eine mögliche genetische Prädisposition 
für subklinische BNP untersucht. Schließlich war nach PregSure® BVD-Impfungen über prominente 
Immunreaktionen berichtet worden. Die vorliegende Studie charakterisierte die Immunantwort 
nach einer PregSure® BVD-Auffrischimpfung auf Transkriptomebene mittels eines RNA-Seq-
Ansatzes, um Einblicke in die strukturelle sowie quantitative Regulation des Blut-Transkriptoms 
sowie weitere Hinweise auf die Impfstoffzusammensetzung zu erhalten. 
Die in einer früheren Studie aufgestellte Hypothese einer genetischen Prädisposition für das 
Hervorbringen von klinischen BNP-Kälbern konnte in dieser Studie bestätigt werden. Die hier 
gewonnenen Ergebnisse legen nahe, dass für eine subklinische BNP ebenfalls eine genetische 
Prädisposition erforderlich ist sowie auch für einen signifikanten Abfall von Thrombozyten- und 
Leukozytenzahlen bei klinisch gesunden Kälbern, die keine Manifestation einer klinischen oder 
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subklinischen BNP zeigen. In der untersuchten Ressourcenpopulation gab es keinen Hinweis auf 
eine höhere Frequenz subklinischer Fälle im Vergleich zu klinischen BNP-Fällen. Weitere 
impfassoziierte epidemiologische Faktoren wie Anzahl an Impfungen oder Zeitpunkt einer 
Impfung während der Trächtigkeit konnten ausgeschlossen werden. Die Transkriptomanalyse 14 
Tage nach Auffrischimpfung mit PregSure® BVD konnte eine koordinierte Reaktion gegen 
doppelsträngige (ds) RNA aufzeigen, obwohl ein inaktivierter Impfstoff gegen das einzelsträngige 
(ss) BVD-RNA-Virus eingesetzt worden war. Der Ursprung der dsRNA ist unbekannt. Entweder 
stammte die dsRNA aus der MDBK-Zelllinie, was die Kontamination der Vakzine mit der für die 
Impfstoffherstellung verwendeten Zelllinie bestätigen würde oder es wurde ein dsRNA-Analogon 
dem Impfstoff zugefügt, um die immunstimulatorischen Eigenschaften der Vakzine zu verbessern. 
Schließlich konnte in der vorliegenden Studie bei allen Tieren ein signifikant hochreguliertes Gen 
mit zytokinartigen Eigenschaften 14 Tage nach Booster-Impfung identifiziert werden. Dieses Gen 
war zuvor bei keiner anderen Spezies beschrieben worden. Zukünftige Untersuchungen sollten 
klären, ob die Hochregulierung dieses Gens spezifisch für eine Immunantwort beim Rind ist und 
ob ein Zusammenhang mit einer PregSure® BVD-Impfung besteht. Abschließend konnte diese 
Studie bestätigen, dass eine genetische Prädisposition seitens PregSure® BVD-geimpfter 
Muttertiere für die Produktion von BNP-Kolostrum erforderlich ist. Daher sollten zukünftige 
Studien genetisch determinierte Unterschiede in der Immunantwort auf exogene Proteine in 
Kombination mit potenten Adjuvanzien zwischen BNP-Kühen und nicht-BNP-Kühen 
berücksichtigen. Hinsichtlich der MHC Klasse I – Hypothese werfen publizierte Beobachtungen die 
Frage auf, ob MHC Klasse I als einziger, kausaler Kandidat für BNP-assoziierte Alloantikörper 
angesehen werden kann. Hierzu bedarf es weiterer Untersuchungen. Die potenziellen 
allogenetischen Effekte einer Vielzahl kontaminierender Proteine in der Vakzine sollten validiert 
werden. 
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